
CLNN Stock Forecast & Price Target
CLNN Analyst Ratings
Bulls say
Clene Inc. presents a favorable outlook due to the statistically significant improvements observed in the REPAIR cohort, where mean NAD+/NADH increased by 8.65% over 12 weeks, indicating a positive impact on cellular energy metabolism relevant to neurodegenerative diseases. Additionally, management's confidence in the current balance sheet to navigate potential future capital raises, coupled with robust safety data and survival benefits associated with their therapeutic programs, bolsters the company's risk-reduction narrative. The solid results from the compassionate use program and the positive long-term follow-up data further underpin the strong potential of Clene's developments, particularly regarding the mechanism of action for its lead therapeutic candidate, CNM-Au8.
Bears say
Clene Inc. reported a net loss of $8.8 million for the third quarter of 2025, which represents an increase in losses compared to $8.0 million in the same period the previous year, reflecting ongoing financial challenges despite reduced R&D and G&A expenses. Notably, the company's Phase 2 trials, HEALEY and RESCUE, failed to meet primary endpoints, raising concerns about the efficacy of its therapeutics aimed at neurodegenerative diseases, even though some secondary endpoints showed potential. The reliance on energy metabolism's role in disease severity, coupled with the ongoing lack of definitive therapeutic success, highlights significant risks and uncertainty surrounding Clene's market prospects and overall financial performance.
This aggregate rating is based on analysts' research of Clene Nanomedicine and is not a guaranteed prediction by Public.com or investment advice.
CLNN Analyst Forecast & Price Prediction
Start investing in CLNN
Order type
Buy in
Order amount
Est. shares
0 shares